Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.